Degradable chemo bead treatment for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial studies a new type of “degradable” chemo bead delivered through a catheter to treat hepatocellular carcinoma (HCC). It aims to check safety and whether the treatment works when surgery or transplant is not an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 19 and 79 years old.
- You agree to join by signing an informed consent form.
- You have confirmed hepatocellular carcinoma (liver cancer) and at least one solid liver lesion larger than 1 cm—typically seen on MRI or contrast CT; if scans are unclear, a biopsy may be needed.
- Your liver function is Child-Pugh A or B (not C), and your cancer is not spread outside the liver or into major blood vessels.
- You can receive follow-up for at least 6 months, and your general condition is ECOG 0–1 (not greater than 1).
- You have no key exclusions like severe kidney disease, uncontrolled bleeding, uncontrolled fluid in the belly, or major MRI/CT/angiogram and contrast-medication problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two treatments for advanced liver cancer that cannot be removed by surgery: drug-coated bead chemoembolization (DEB-TACE) and a chemotherapy infusion into the liver artery (SALOX-HAIC). The goal is to see if this combination can help shrink tumors and improve outcomes.
This trial compares two types of tiny beads used in a liver cancer treatment called TACE to see which works better. If you have liver cancer that needs TACE and your liver is still working fairly well, you may be able to join.
This trial tests combining Yttrium-90 microspheres (tiny radioactive beads delivered into the liver), immunotherapy (drugs that help your immune system fight cancer), and anti-angiogenesis drugs (medicines that block blood supply to tumors) followed by a liver-directed chemotherapy infusion. It is designed for people with hepatocellular carcinoma (liver cancer) that cannot be removed with surgery yet may become operable after this treatment.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
This trial tests a treatment called yttrium-90 carbon microsphere radioembolization for people with liver cancer that has been previously treated. Tiny radioactive beads are delivered directly to the tumor through the blood vessels to destroy cancer cells from inside. This may be an option if your liver cancer has not spread beyond the liver and you can tolerate the procedure.
This trial tests a combination of liver-directed therapy (TACE) with two drugs—bevacizumab (Avastin) and atezolizumab (Tecentriq)—as a first treatment for liver cancer that cannot be removed by surgery. The goal is to see if this approach helps shrink tumors and control the disease longer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.